Peptide Dosing & Regimen References
Source-reported dosing schedules, published studies, and formulation context for all listed compounds.
Research Stack Consultation
Explore scientific literature by research objective and compound. Select your interests and prepare a consultation request for the LMK research team.
Open Research Stack Consultation →Scientific literature review only. No individualized human-use stacking or dosing instructions.
01. Retatrutide (LY3437943)— Dosing and regimen
Source-reported dosing and regimen
Phase 2 trial: once weekly, subcutaneous; 48-week trial
| Period | Reported amount |
|---|---|
| Weeks 1–4 | 2 mg |
| Weeks 5–8 | 4 mg |
| Weeks 9–12 | 8 mg |
| Week 13 onward | 12 mg |
This is the lower-start 12 mg study arm. The source also lists a Phase 3 sequence: 2, 4, 6, 9, then 12 mg weekly, with each escalation after four weeks.
Reconstitution by catalog vial size
10 mg powder vial
Source-listed reconstitution amount: 1 mL bacteriostatic water.
Resulting concentration used by the source: 10 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 2 | 0.2 | 20 |
| Weeks 5–8 | 4 | 0.4 | 40 |
| Weeks 9–12 | 8 | 0.8 | 80 |
| Week 13 onward | 12 | 1.2 — exceeds one vial | 120 — exceeds a 1 mL / 100 U syringe |
| Alternative Phase 3: weeks 9–12 | 6 | 0.6 | 60 |
| Alternative Phase 3: weeks 13–16 | 9 | 0.9 | 90 |
20 mg powder vial
Source-listed reconstitution amount: 2 mL bacteriostatic water.
Resulting concentration used by the source: 10 mg/mL.
PeptideDosages.com — 20 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 2 | 0.2 | 20 |
| Weeks 5–8 | 4 | 0.4 | 40 |
| Weeks 9–12 | 8 | 0.8 | 80 |
| Week 13 onward | 12 | 1.2 | 120 — exceeds a 1 mL / 100 U syringe |
| Alternative Phase 3: weeks 9–12 | 6 | 0.6 | 60 |
| Alternative Phase 3: weeks 13–16 | 9 | 0.9 | 90 |
30 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 10 mg/mL.
PeptideDosages.com — 30 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 2 | 0.2 | 20 |
| Weeks 5–8 | 4 | 0.4 | 40 |
| Weeks 9–12 | 8 | 0.8 | 80 |
| Week 13 onward | 12 | 1.2 | 120 — exceeds a 1 mL / 100 U syringe |
| Alternative Phase 3: weeks 9–12 | 6 | 0.6 | 60 |
| Alternative Phase 3: weeks 13–16 | 9 | 0.9 | 90 |
Protocol source: PeptideDosages.com — retatrutide 10 mg vial.
Overview
Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors. Clinical research has investigated its effects on body weight and metabolic outcomes.
Published Phase 2 Trial — Historical Study Reference
Jastreboff et al. (2023), DOI: 10.1056/NEJMoa2301972. Adults with obesity received study-manufactured retatrutide or placebo for 48 weeks under the trial protocol.
| Study target dose | Starting doses studied | Trial frequency |
|---|---|---|
| 1 mg | 1 mg | Once weekly |
| 4 mg | 2 mg or 4 mg, by trial arm | Once weekly |
| 8 mg | 2 mg or 4 mg, by trial arm | Once weekly |
| 12 mg | 2 mg | Once weekly |
Research and practical considerations
- Clinical-trial outcomes included substantial average weight reduction.
- Gastrointestinal adverse events were common and dose-related.
- Heart-rate changes were also observed in clinical research.
- Vial size alone does not establish drug concentration or an appropriate dose.
References
02. AOD-9604 — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; morning, fasted
| Period | Reported amount |
|---|---|
| Weeks 1–4 | 0.3 mg/day |
| Weeks 5–12 | 0.5 mg/day |
Reconstitution by catalog vial size
5 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 1.6667 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 0.3 | 0.18 | 18 |
| Weeks 5–12 | 0.5 | 0.3 | 30 |
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 0.3 | 0.09 | 9 |
| Weeks 5–12 | 0.5 | 0.15 | 15 |
Protocol source: PeptideDosages.com — aod 9604 5 mg vial.
Overview
AOD-9604 is a modified fragment of human growth hormone investigated primarily in obesity and fat-metabolism research.
Research Considerations
- Route of administration and formulation matter when comparing studies.
- Online dosing tables should not be treated as equivalent to published clinical protocols.
- Claims about exercise timing and fat-burning effects require supporting clinical evidence.
- Research findings should be interpreted in the context of the original study.
References
03. Tesamorelin (TH9507)— Dosing and regimen
Source-reported dosing and regimen
Phase 3 research: daily, subcutaneous
| Period | Reported amount |
|---|---|
| Weeks 1–26 | 2 mg/day |
Extension research continued through 52 weeks; regulated-product formulations have separate labeling.
Reconstitution by catalog vial size
5 mg powder vial
Source-listed reconstitution amount: 2.5 mL bacteriostatic water.
Resulting concentration used by the source: 2 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–26 | 2 | 1 | 100 |
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–26 | 2 | 0.6 | 60 |
Protocol source: PeptideDosages.com — tesamorelin 5 mg vial.
Overview
Tesamorelin (TH9507) is a growth-hormone-releasing factor analogue investigated for its effects on growth-hormone signaling and visceral abdominal fat.
Research Considerations
- Tesamorelin stimulates growth-hormone and IGF-1 signaling.
- Clinical research has evaluated visceral abdominal fat and metabolic outcomes.
- Glucose regulation, IGF-1 levels, fluid retention, and injection-site reactions are relevant monitoring topics.
References
04. CJC-1295 with DAC (DAC:GRF) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: once weekly, subcutaneous; evening
| Period | Reported amount |
|---|---|
| Weeks 1–12 | 2 mg/week |
Reconstitution by catalog vial size
2 mg powder vial
Source-listed reconstitution amount: 1 mL bacteriostatic water.
Resulting concentration used by the source: 2 mg/mL.
PeptideDosages.com — 2 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–12 | 2 | 1 | 100 |
5 mg powder vial
Source-listed reconstitution amount: 2 mL bacteriostatic water.
Resulting concentration used by the source: 2.5 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–12 | 2 | 0.8 | 80 |
10 mg powder vial
Calculated reconstitution volume: 4 mL.
Calculated concentration: 2.5 mg/mL. Matches the 5 mg reference vial at 2 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–12 | 2 | 0.8 | 80 |
Protocol source: PeptideDosages.com — cjc 1295 dac 2 mg vial.
Overview
CJC-1295 with DAC (DAC:GRF) is a long-acting growth-hormone-releasing hormone analogue. The drug-affinity complex extends exposure and distinguishes it from short-acting products marketed as CJC-1295 without DAC.
Published Human Research
| Research Feature | Study Description |
|---|---|
| Participants | Healthy adult volunteers |
| Administration | Single ascending doses and repeated weekly or biweekly dosing |
| Measures | Growth hormone, IGF-1, pharmacokinetics, and tolerability |
The foundational clinical study evaluated weight-based research doses, including 30 and 60 micrograms/kg. Those study doses do not establish a general-purpose bodybuilding or wellness schedule.
Key Considerations
- DAC changes the duration of exposure; it should not be confused with a no-DAC formulation.
- Growth hormone and IGF-1 changes are biological measures, not proof of improved performance.
- Repeated dosing can produce cumulative effects on IGF-1.
References
CJC-1295 without DAC (often modified GRF(1-29)) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; bedtime
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 0.1 mg/day |
| Weeks 3–4 | 0.15 mg/day |
| Weeks 5–6 | 0.2 mg/day |
| Weeks 7–12 | 0.25–0.3 mg/day |
Reconstitution by catalog vial size
5 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 1.6667 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.1 | 0.06 | 6 |
| Weeks 3–4 | 0.15 | 0.09 | 9 |
| Weeks 5–6 | 0.2 | 0.12 | 12 |
| Weeks 7–12 | 0.25–0.3 | 0.15–0.18 | 15–18 |
10 mg powder vial
Calculated reconstitution volume: 6 mL.
Calculated concentration: 1.6667 mg/mL. Matches the 5 mg reference vial at 3 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.1 | 0.06 | 6 |
| Weeks 3–4 | 0.15 | 0.09 | 9 |
| Weeks 5–6 | 0.2 | 0.12 | 12 |
| Weeks 7–12 | 0.25–0.3 | 0.15–0.18 | 15–18 |
Protocol source: PeptideDosages.com — cjc 1295 no dac 5 mg vial.
Overview
Products marketed as CJC-1295 without DAC are commonly described as modified GRF(1-29), a shorter-acting growth-hormone-releasing hormone analogue. The precise chemical identity and formulation should be confirmed from the manufacturer's specifications.
Research considerations
- Verify exact molecular identity; marketing names can be inconsistent.
- Do not assume that findings from DAC-containing CJC-1295 studies apply to modified GRF(1-29).
- Clinical evidence for nonapproved uses and long-term safety remains limited.
Research references
05. Ipamorelin (NNC 26-0161) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; 30–60 minutes before bed, fasted
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 0.1 mg/day |
| Weeks 3–4 | 0.15 mg/day |
| Weeks 5–8 | 0.2 mg/day |
| Weeks 9–12 | 0.25 mg/day |
Reconstitution by catalog vial size
2 mg powder vial
Calculated reconstitution volume: 1.2 mL.
Calculated concentration: 1.6667 mg/mL. Matches the 5 mg reference vial at 3 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.1 | 0.06 | 6 |
| Weeks 3–4 | 0.15 | 0.09 | 9 |
| Weeks 5–8 | 0.2 | 0.12 | 12 |
| Weeks 9–12 | 0.25 | 0.15 | 15 |
5 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 1.6667 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.1 | 0.06 | 6 |
| Weeks 3–4 | 0.15 | 0.09 | 9 |
| Weeks 5–8 | 0.2 | 0.12 | 12 |
| Weeks 9–12 | 0.25 | 0.15 | 15 |
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.1 | 0.03 | 3 |
| Weeks 3–4 | 0.15 | 0.045 | 4.5 |
| Weeks 5–8 | 0.2 | 0.06 | 6 |
| Weeks 9–12 | 0.25 | 0.075 | 7.5 |
Protocol source: PeptideDosages.com — ipamorelin 5 mg vial.
Overview
Ipamorelin (NNC 26-0161) is a growth-hormone secretagogue that acts through the ghrelin receptor. Research has examined growth-hormone release and gastrointestinal applications.
Research Considerations
- Route of administration and study population affect interpretation of research findings.
- Growth-hormone release does not automatically demonstrate muscle gain or faster recovery.
- Combination protocols with CJC-1295 should not be assumed to have the same evidence as either ingredient alone.
References
06. SS-31 (Elamipretide) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 5 mg/day |
| Weeks 3–8 | 10 mg/day |
Reconstitution by catalog vial size
10 mg powder vial
Source-listed reconstitution amount: 1 mL bacteriostatic water.
Resulting concentration used by the source: 10 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 5 | 0.5 | 50 |
| Weeks 3–8 | 10 | 1 | 100 |
50 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 16.6667 mg/mL.
PeptideDosages.com — 50 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 5 | 0.3 | 30 |
| Weeks 3–8 | 10 | 0.6 | 60 |
Protocol source: PeptideDosages.com — ss 31 10 mg vial.
Overview
SS-31, also known as elamipretide and previously studied under the code name MTP-131, is a mitochondria-targeting tetrapeptide studied for its interaction with cardiolipin and mitochondrial membrane function.
Approved Product Dose and Indication
| Product | Labeled Dose | Population and Indication |
|---|---|---|
| FORZINITY (elamipretide) | 40 mg once daily | Adults and pediatric patients with Barth syndrome weighing at least 30 kg |
| Severe renal impairment in adults, not on dialysis | 20 mg once daily | Formulation-specific dose modification in the product label |
The labeled dose applies to FORZINITY, the regulated elamipretide product. Its approved indication is specific to Barth syndrome. The source-listed research vial amounts above are separate entries and should not be interpreted as FORZINITY dosing instructions.
Research Considerations
- Elamipretide has been studied for its effects on mitochondrial function and cardiolipin interactions.
- Research findings in specific diseases do not establish benefits for general wellness, anti-aging, exercise recovery, or athletic performance.
- Research protocols and regulated product labeling describe different contexts and should be evaluated separately.
References
07. MOTS-C — Dosing and regimen
Source-reported dosing and regimen
Illustrative calculation sequence: one administration daily
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 0.2 mg |
| Weeks 3–4 | 0.4 mg |
| Weeks 5–6 | 0.6 mg |
| Weeks 7–8 | 0.8 mg |
| Weeks 9–10+ | 1 mg |
The source presents this as measurement arithmetic, rather than a validated human regimen.
Reconstitution by catalog vial size
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.2 | 0.06 | 6 |
| Weeks 3–4 | 0.4 | 0.12 | 12 |
| Weeks 5–6 | 0.6 | 0.18 | 18 |
| Weeks 7–8 | 0.8 | 0.24 | 24 |
| Weeks 9–10+ | 1 | 0.3 | 30 |
20 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 6.6667 mg/mL.
PeptideDosages.com — 20 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.2 | 0.03 | 3 |
| Weeks 3–4 | 0.4 | 0.06 | 6 |
| Weeks 5–6 | 0.6 | 0.09 | 9 |
| Weeks 7–8 | 0.8 | 0.12 | 12 |
| Weeks 9–10+ | 1 | 0.15 | 15 |
Protocol source: PeptideDosages.com — mots c 10 mg vial.
Overview
MOTS-C is a mitochondrial-derived peptide investigated for its role in metabolic regulation, cellular stress responses, and pathways associated with insulin sensitivity.
Research Considerations
- AMPK signaling and glucose metabolism are key research topics.
- Animal findings do not establish human weight-loss, endurance, or longevity benefits.
- Human pharmacokinetics, safety, and an appropriate clinical dose remain insufficiently characterized.
References
08. NAD+ (Nicotinamide Adenine Dinucleotide, Oxidized Form) — Dosing and regimen
Source-reported dosing and regimen
Community-reported calculation sequence: one administration daily
| Period | Reported amount |
|---|---|
| Week 1 | 50 mg |
| Week 2 | 75 mg |
| Weeks 3–16 | 100 mg |
The source supplies injection-volume calculations, rather than an established clinical schedule.
Reconstitution by catalog vial size
500 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 166.6667 mg/mL.
PeptideDosages.com — 500 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Week 1 | 50 | 0.3 | 30 |
| Week 2 | 75 | 0.45 | 45 |
| Weeks 3–16 | 100 | 0.6 | 60 |
1000 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 333.3333 mg/mL.
PeptideDosages.com — 1000 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Week 1 | 50 | 0.15 | 15 |
| Week 2 | 75 | 0.225 | 22.5 |
| Weeks 3–16 | 100 | 0.3 | 30 |
Protocol source: PeptideDosages.com — nad 500 mg 10ml vial.
Overview
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular redox reactions, energy metabolism, and several enzymes involved in cellular maintenance. NAD+ is the oxidized form; NADH is its reduced form. NAD+ is not a peptide.
Research Context by Form
| Form | Dosing Reference | Evidence Context |
|---|---|---|
| Oral NAD+ and related precursors | Varies by compound and study | Do not equate NAD+ with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). |
| Intravenous NAD+ | Protocols vary by clinic and formulation | Evidence supporting many wellness claims remains limited. |
| Subcutaneous NAD+ | No standardized general-purpose regimen established | Formulation and route require separate evaluation. |
Research Considerations
- NAD+ biology does not by itself establish that NAD+ administration improves energy, aging, or cognition.
- Research on NR or NMN should not be presented as direct evidence for injected NAD+.
- Administration route, product formulation, and study endpoints matter when interpreting research.
References
09. FOXO4-DRI (FOXO4 D-Retro-Inverso Peptide) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous
| Period | Reported amount |
|---|---|
| Weeks 1–4 | 0.25 mg/day |
| Weeks 5–8 | 0.375 mg/day |
| Weeks 9–16 | 0.5 mg/day |
Reconstitution by catalog vial size
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 0.25 | 0.075 | 7.5 |
| Weeks 5–8 | 0.375 | 0.1125 | 11.25 |
| Weeks 9–16 | 0.5 | 0.15 | 15 |
Protocol source: PeptideDosages.com — foxo4 dri 10 mg vial.
Overview
FOXO4-DRI is an experimental D-retro-inverso peptide designed to interfere with interactions between FOXO4 and p53. Research has investigated its potential effects on senescent-cell survival pathways.
Research Evidence
- Foundational research examined cellular systems and aged mice.
- Studies investigated senescent-cell survival pathways and tissue outcomes.
- These findings do not establish a human dose or prove human anti-aging effects.
Handling and Storage Considerations
Storage conditions depend on the specific product, packaging, and manufacturer documentation. Follow validated manufacturer instructions for lyophilized material and any prepared solution. Generic storage recommendations do not establish a validated stability period.
References
10. GLOW (GHK-Cu / BPC-157 / TB-500 Blend) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; four weeks
| Period | Reported amount |
|---|---|
| Weeks 1–4 | Approximately 2.33 mg total blend/day |
Source formula: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 per 70 mg vial. Daily component amounts: approximately 1.67 mg GHK-Cu and 0.333 mg each BPC-157 and TB-500.
Reconstitution by catalog vial size
70 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 23.3333 mg/mL.
PeptideDosages.com — 70 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–4 | 2.3333 | 0.1 | 10 |
Protocol source: PeptideDosages.com — glow peptide blend 70 mg vial.
Overview and composition
GLOW is a marketing name commonly used for a combination of GHK-Cu, BPC-157, and TB-500 or thymosin-related material. It is not a single standardized compound and has no separate established scientific or generic drug name. Composition, ingredient identity, and amounts may vary among suppliers. Verify the actual product specification before comparing reported protocols.
Research considerations
- Evidence relating to an individual ingredient does not establish the effectiveness or safety of the combined blend.
- GHK-Cu research involving topical formulations does not establish the effects of injectable use.
- TB-500 is a market name; confirm the exact molecular identity and specification with the manufacturer.
- Blend stability, ingredient compatibility, and sterility require product-specific data.
References
11. KLOW (GHK-Cu / BPC-157 / TB-500 / KPV Blend) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; 12-week chart
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 2 mg total/day: GHK-Cu 1.25 mg; BPC-157, TB-500 and KPV 0.25 mg each |
| Weeks 3–4 | 4 mg total/day: GHK-Cu 2.5 mg; BPC-157, TB-500 and KPV 0.5 mg each |
| Weeks 5–8 | 6 mg total/day: GHK-Cu 3.75 mg; BPC-157, TB-500 and KPV 0.75 mg each |
| Weeks 9–12 | 4 mg total/day: GHK-Cu 2.5 mg; BPC-157, TB-500 and KPV 0.5 mg each |
Amounts follow the detailed component table, not the inconsistent headline range. Source formula: 50 mg GHK-Cu + 10 mg each BPC-157, TB-500 and KPV.
Reconstitution by catalog vial size
80 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 26.6667 mg/mL.
PeptideDosages.com — 80 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 2 | 0.075 | 7.5 |
| Weeks 3–4 | 4 | 0.15 | 15 |
| Weeks 5–8 | 6 | 0.225 | 22.5 |
| Weeks 9–12 | 4 | 0.15 | 15 |
Protocol source: PeptideDosages.com — klow 80 mg vial.
Overview and composition
KLOW is a marketing name for a multi-ingredient blend. Commonly advertised formulations include GHK-Cu, BPC-157, TB-500 or thymosin-related material, and KPV. KLOW is not a single standardized compound and has no separate established scientific or generic drug name. Ingredient identity, ratios, and total vial content may differ among suppliers. Verify the manufacturer's specification for the actual product.
KLOW 80 mg — Four-ingredient composition reference
The supplied formulation describes an 80 mg total blend containing 50 mg GHK-Cu and 10 mg each of KPV, BPC-157, and TB-500 (a 5:1:1:1 ratio when ordered GHK-Cu : KPV : BPC-157 : TB-500). “KLOW” is a product name rather than a standardized scientific acronym; the amounts and ingredient identities should be checked against the actual manufacturer's batch specification.
| Ingredient | Amount per 80 mg vial | Research mechanism / evidence context |
|---|---|---|
| K — KPV | 10 mg | Tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH); studied in preclinical inflammatory signaling, including NF-κB-related pathways, and gastrointestinal models. Clinical benefits are not established. |
| L — GHK-Cu | 50 mg | Copper-binding tripeptide investigated for extracellular-matrix signaling, collagen-related pathways, and tissue remodeling. Copper complexes can contribute a blue color in solution; appearance alone does not verify identity or purity. |
| O — BPC-157 | 10 mg | Experimental pentadecapeptide studied predominantly in animal and laboratory models involving gastrointestinal tissue, tendons, and angiogenesis. Human efficacy and safety are not established. |
| W — TB-500 | 10 mg | Marketed thymosin-β4-related peptide; exact fragment identity varies by supplier. Thymosin-related pathways include actin regulation and cell migration, but claims of rapid human tissue recovery are not clinically established. |
Research considerations
- Individual ingredient studies do not establish the effects or safety of the combined product.
- Product identity, component ratios, and batch consistency are central to interpreting research.
- TB-500 is a market name; confirm the exact molecular identity and manufacturer specification.
- Concentration calculations must use the actual total amount and final solution volume, not a generic KLOW formula.
- Blend stability, compatibility, and sterility require product-specific evidence.
References
12. BPC-157 (Body Protection Compound-157) — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 0.2 mg/day |
| Weeks 3–4 | 0.4 mg/day |
| Weeks 5–8+ | 0.6 mg/day |
Reconstitution by catalog vial size
5 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 1.6667 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.2 | 0.12 | 12 |
| Weeks 3–4 | 0.4 | 0.24 | 24 |
| Weeks 5–8+ | 0.6 | 0.36 | 36 |
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.2 | 0.06 | 6 |
| Weeks 3–4 | 0.4 | 0.12 | 12 |
| Weeks 5–8+ | 0.6 | 0.18 | 18 |
Protocol source: PeptideDosages.com — bpc 157 5 mg vial.
Overview
BPC-157 is a synthetic 15-amino-acid peptide studied primarily in preclinical gastrointestinal, tendon, ligament, and musculoskeletal injury models. The name is commonly expanded as "Body Protection Compound-157." It does not have an established generic drug name.
Research evidence
- Animal studies have investigated tendon, ligament, muscle, and gastrointestinal outcomes.
- Mechanistic studies have examined angiogenesis, fibroblast activity, and inflammatory pathways.
- Human evidence remains limited and does not establish an optimal dose, route, or treatment duration.
- Findings from preclinical studies cannot by themselves establish safety or effectiveness in humans.
Handling and product considerations
- Follow the manufacturer's documented storage conditions for the specific formulation.
- Do not assign a universal refrigerated shelf life without formulation-specific stability evidence.
- For injectable products, identity and purity testing are distinct from sterility and endotoxin testing.
- Vial strength alone does not establish product quality, sterility, or suitability for human use.
References
13. Selank — Dosing and regimen
Source-reported dosing and regimen
Registered-product schedule reference: intranasal, three times daily
| Period | Reported amount |
|---|---|
| Days 1–14 | 0.3 mg per administration; 0.9 mg/day |
Reference formulation: 0.15% (1.5 mg/mL) Selank drops. A custom spray is not equivalent to the registered formulation.
Reconstitution by catalog vial size
5 mg powder vial
Source-listed nasal reconstitution: 3 mL compatible sterile nasal vehicle initially, then transfer and bring to a measured final volume of 3.33 (approximately) mL in a suitable nasal bottle. Reference concentration: 1.5 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | Nasal route |
|---|---|---|---|
| Days 1–14 | 0.3 | 0.2 | Not applicable |
10 mg powder vial
Source-listed nasal reconstitution: 3 mL compatible sterile nasal vehicle initially, then transfer and bring to a measured final volume of 6.67 (approximately) mL in a suitable nasal bottle. Reference concentration: 1.5 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | Nasal route |
|---|---|---|---|
| Days 1–14 | 0.3 | 0.2 | Not applicable |
Protocol source: PeptideDosages.com — selank 5 mg vial.
Overview
A synthetic peptide investigated in neurobehavioral research.
Selected published evidence
A 2008 comparative study enrolled 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 received medazepam. The abstract reports psychometric and biochemical assessments.
Evidence limitations
This selected study is small. Its indexed abstract does not supply a complete preparation and administration protocol; it does not establish a regimen for LMK materials.
Primary references
14. Semax — Dosing and regimen
Source-reported dosing and regimen
Registered-product schedule reference: intranasal, 2–3 times in the first half of the day
| Period | Reported amount |
|---|---|
| Days 1–5 | 0.2–0.3 mg per administration; 0.4–0.9 mg/day |
Reference formulation: 0.1% (1 mg/mL) Semax drops. A custom spray is not equivalent to the registered formulation.
Reconstitution by catalog vial size
5 mg powder vial
Source-listed nasal reconstitution: 3 mL compatible sterile nasal vehicle initially, then transfer and bring to a measured final volume of 5 mL in a suitable nasal bottle. Reference concentration: 1 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | Nasal route |
|---|---|---|---|
| Days 1–5 | 0.2–0.3 | 0.2–0.3 | Not applicable |
10 mg powder vial
Source-listed nasal reconstitution: 3 mL compatible sterile nasal vehicle initially, then transfer and bring to a measured final volume of 10 mL in a suitable nasal bottle. Reference concentration: 1 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | Nasal route |
|---|---|---|---|
| Days 1–5 | 0.2–0.3 | 0.2–0.3 | Not applicable |
Protocol source: PeptideDosages.com — semax 5 mg vial.
Overview
An ACTH-derived peptide investigated in experimental neuroscience.
Selected published evidence
A 2014 experiment examined gene-expression changes in rats following focal cerebral ischemia. It evaluated immune and vascular pathways in an animal model.
Evidence limitations
Rat gene-expression findings are not evidence of a safe human regimen or established cognitive benefit. Study route, model, timing, and endpoints must be considered together.
Primary references
15. Glutathione — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 100 mg/day |
| Weeks 3–4 | 150 mg/day |
| Weeks 5–8 | 200 mg/day |
The source separately mentions maintenance at 200 mg once or twice weekly.
Reconstitution by catalog vial size
400 mg powder vial
Calculated reconstitution volume: 1.3333 mL (approximately).
Calculated concentration: 300 mg/mL. Matches the 600 mg reference vial at 2 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 100 | 0.3333 | 33.33 |
| Weeks 3–4 | 150 | 0.5 | 50 |
| Weeks 5–8 | 200 | 0.6667 | 66.67 |
600 mg powder vial
Source-listed reconstitution amount: 2 mL bacteriostatic water.
Resulting concentration used by the source: 300 mg/mL.
PeptideDosages.com — 600 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 100 | 0.3333 | 33.33 |
| Weeks 3–4 | 150 | 0.5 | 50 |
| Weeks 5–8 | 200 | 0.6667 | 66.67 |
1500 mg powder vial
Calculated reconstitution volume: 5 mL.
Calculated concentration: 300 mg/mL. Matches the 600 mg reference vial at 2 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 100 | 0.3333 | 33.33 |
| Weeks 3–4 | 150 | 0.5 | 50 |
| Weeks 5–8 | 200 | 0.6667 | 66.67 |
Protocol source: PeptideDosages.com — glutathione 600 mg vial.
Overview
An endogenous tripeptide involved in cellular redox biology; it is distinct from peptide receptor agonists.
Selected published evidence
Richie et al. studied oral glutathione for six months in 54 healthy nonsmoking adults. A separate controlled oral trial reported no significant changes in the measured oxidative-stress biomarkers or glutathione status.
Evidence limitations
Results vary with study design and formulation. Oral capsule studies do not establish injectable dosing, reconstitution, or equivalence to a lyophilized research vial.
Primary references
16. DSIP — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; evening before bed
| Period | Reported amount |
|---|---|
| Week 1 | 0.1 mg/day |
| Week 2 | 0.15 mg/day |
| Week 3 | 0.2 mg/day |
| Weeks 4–8 | 0.25–0.3 mg/day |
Reconstitution by catalog vial size
5 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 1.6667 mg/mL.
PeptideDosages.com — 5 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Week 1 | 0.1 | 0.06 | 6 |
| Week 2 | 0.15 | 0.09 | 9 |
| Week 3 | 0.2 | 0.12 | 12 |
| Weeks 4–8 | 0.25–0.3 | 0.15–0.18 | 15–18 |
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Week 1 | 0.1 | 0.03 | 3 |
| Week 2 | 0.15 | 0.045 | 4.5 |
| Week 3 | 0.2 | 0.06 | 6 |
| Weeks 4–8 | 0.25–0.3 | 0.075–0.09 | 7.5–9 |
Protocol source: PeptideDosages.com — dsip 5 mg vial.
Overview
Delta sleep-inducing peptide, studied in experimental sleep physiology.
Selected published evidence
A 1992 double-blind study examined 16 patients with chronic insomnia. It reported weak changes in selected objective measures, without improvement in subjective sleep quality, and questioned major therapeutic benefit.
Evidence limitations
A small historical study does not establish a routine insomnia treatment or the suitability of a modern research product. Its route cannot be substituted with another administration route.
Primary references
17. Epitalon — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; evening
| Period | Reported amount |
|---|---|
| Days 1–20 | 5 mg/day |
| Following 4–6 months | Off cycle |
The source describes approximately two cycles per year.
Reconstitution by catalog vial size
10 mg powder vial
Source-listed reconstitution amount: 2 mL bacteriostatic water.
Resulting concentration used by the source: 5 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Days 1–20 | 5 | 1 | 100 |
| Following 4–6 months | 0 | 0 | 0 |
50 mg powder vial
Calculated reconstitution volume: 10 mL.
Calculated concentration: 5 mg/mL. Matches the 10 mg reference vial at 2 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Days 1–20 | 5 | 1 | 100 |
| Following 4–6 months | 0 | 0 | 0 |
Protocol source: PeptideDosages.com — epitalon epithalon 10 mg vial.
Overview
Also spelled Epithalon; a tetrapeptide investigated in cellular aging and gene-regulation research.
Selected published evidence
A 2003 study reported telomerase-related changes in cultured human fetal fibroblasts. A 2025 study investigated telomere mechanisms in normal and cancer-derived cell lines.
Evidence limitations
Cultured human cells are not human clinical participants. Telomere changes in vitro do not demonstrate longer life, clinical benefit, or a safe human dosing cycle.
Primary references
18. IGF-1 LR3 — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; eight-week chart
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 0.02 mg/day |
| Weeks 3–4 | 0.04 mg/day |
| Weeks 5–8 | 0.05 mg/day |
Reconstitution by catalog vial size
0.1 mg powder vial (catalog label: 100 mcg)
Calculated reconstitution volume: 0.3 mL.
Calculated concentration: 0.3333 mg/mL. Matches the 1 mg reference vial at 3 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.02 | 0.06 | 6 |
| Weeks 3–4 | 0.04 | 0.12 | 12 |
| Weeks 5–8 | 0.05 | 0.15 | 15 |
1 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 0.3333 mg/mL.
PeptideDosages.com — 1 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.02 | 0.06 | 6 |
| Weeks 3–4 | 0.04 | 0.12 | 12 |
| Weeks 5–8 | 0.05 | 0.15 | 15 |
Protocol source: PeptideDosages.com — igf 1 lr3 1 mg vial.
Overview
Long R3 IGF-I, a modified IGF-I analogue investigated in receptor and binding-protein research.
Selected published evidence
Experimental studies compared IGF-I analogues with altered binding-protein affinity. A porcine study reported effects that differed from those described in rats, highlighting model dependence.
Evidence limitations
LR3 is not interchangeable with native IGF-I or a prescribed IGF-I medicine. Animal and cellular results do not establish a human performance-enhancement regimen.
Primary references
19. Wolverine — Dosing and regimen
Source-reported dosing and regimen
Community-reported: daily, subcutaneous; eight weeks
| Period | Reported amount |
|---|---|
| Weeks 1–2 | 0.5 mg total/day; 0.25 mg each |
| Weeks 3–4 | Approximately 0.667 mg total/day; 0.333 mg each |
| Weeks 5–8 | 1 mg total/day; 0.5 mg each |
Wolverine comparison assumes the source’s 1:1 BPC-157/TB-500 blend (5 mg each in a 10 mg vial). Apply component amounts only when the actual product has that ratio.
Reconstitution by catalog vial size
Reference formula for the 10 mg blend: 5 mg BPC-157 + 5 mg TB-500. Confirm the actual blend ratio matches.
5 mg powder vial
Calculated reconstitution volume: 1.5 mL.
Calculated concentration: 3.3333 mg/mL. Matches the 10 mg reference vial at 3 mL.
Calculator-checked conversion · Reference concentration
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.5 | 0.15 | 15 |
| Weeks 3–4 | 0.6667 | 0.2 | 20 |
| Weeks 5–8 | 1 | 0.3 | 30 |
10 mg powder vial
Source-listed reconstitution amount: 3 mL bacteriostatic water.
Resulting concentration used by the source: 3.3333 mg/mL.
PeptideDosages.com — 10 mg reference
| Period | Amount per administration (mg) | Volume (mL) | U-100 syringe marking (U) |
|---|---|---|---|
| Weeks 1–2 | 0.5 | 0.15 | 15 |
| Weeks 3–4 | 0.6667 | 0.2 | 20 |
| Weeks 5–8 | 1 | 0.3 | 30 |
Protocol source: PeptideDosages.com — bpc 157 tb 500 10mg blend.
Overview
LMK identifies Wolverine as a blend of BPC-157 and TB-500. The blend name is not a standardized molecular identity.
Selected published evidence
Selected ingredient literature includes BPC-157 in rat tendon injury and full-length thymosin beta-4 in rat skin wounds. These publications studied different materials separately, not the LMK Wolverine blend.
Evidence limitations
TB-500 naming does not establish equivalence to full-length thymosin beta-4. Ingredient results do not establish blend efficacy, compatibility, stability, component ratios, or human safety.